Talanta, Journal Year: 2024, Volume and Issue: 284, P. 127247 - 127247
Published: Nov. 19, 2024
Language: Английский
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(22), P. 12379 - 12379
Published: Nov. 18, 2024
Parkinson's disease (PD) is a progressive neurological that causes both motor and nonmotor symptoms. While our understanding of putative mechanisms has advanced significantly, it remains challenging to verify biomarkers with sufficient evidence for regular clinical use. Clinical symptoms are the primary basis diagnosing disease, which can be mild in early stages overlap other disorders. As result, testing medical records mostly relied upon diagnosis, posing substantial challenges during initial diagnosis continuous monitoring. Recent biochemical, neuroimaging, genetic have helped us understand pathophysiology disease. This comprehensive study focuses on these biomarkers, were chosen based their relevance, methodological excellence, contribution field. Biochemical including α-synuclein glial fibrillary acidic protein (GFAP), predict severity progression. The dopaminergic system widely used as neuroimaging biomarker diagnose PD. Numerous genes genome wide association (GWAS) sites been related development research SNCA gene leucine-rich repeat kinase 2 (LRRK2) shown promising results. By evaluating current studies, this review intends uncover gaps validation use, while also highlighting improvements. It emphasizes need dependable reproducible indicators improving PD prognosis. These may open up new avenues progression tracking, personalized treatment programs.
Language: Английский
Citations
5
Sensing and Bio-Sensing Research, Journal Year: 2024, Volume and Issue: unknown, P. 100717 - 100717
Published: Nov. 1, 2024
Language: Английский
Citations
5
Advanced Materials Technologies, Journal Year: 2025, Volume and Issue: unknown
Published: April 17, 2025
Abstract In today's technologically advanced era, the demand for swift and precise analyses spans scientific research industrial applications alike. Surface plasmon resonance (SPR) technology has surged in popularity, due to its real‐time measurement capabilities with exceptional sensitivity label‐free operation. These attributes have propelled SPR into prominence across diverse fields including medical diagnostics, pharmaceuticals, food safety, environmental monitoring of hazardous compounds. Here key principles behind are delved, workings SPR‐based sensors elucidated. Additionally, latest advancements biosensors tailored detecting a variety analytes, focus on dopamine (DA) α‐synuclein, which hold particular significance context neurological disorders, examined. potential breakthroughs discussed, thanks integration nanomaterials, lab‐on‐a‐chip devices, multiplexing formats, machine learning. Finally, new modes discussed based subwavelength structures leveraging guided mode (GMR), surface lattice (SLR), bound state continuum (BIC) their applications, particularly nonplasmonic refractive index biosensors.
Language: Английский
Citations
0
Biosensors, Journal Year: 2025, Volume and Issue: 15(5), P. 280 - 280
Published: April 29, 2025
Parkinson’s disease (PD), a neurodegenerative disorder marked by the progressive loss of dopaminergic neurons in substantia nigra, imposes substantial economic burdens, including both direct and indirect costs. The medical community currently lacks definitive cure for disease, early detection is crucial timely intervention management. As innovative diagnostic tools, biosensors have shown great potential detecting PD at its stages. This review comprehensively summarizes recent advances PD, with particular focus on two key biomarkers: dopamine (DA) α-synuclein (α-syn). Furthermore, it illustrates variety nanotechnology-based biosensors, optical, electrochemical, transistor detailing their underlying principles, advantages, limitations, applications detection. Moreover, explores challenges prospects advancing diagnosis.
Language: Английский
Citations
0
npj Parkinson s Disease, Journal Year: 2024, Volume and Issue: 10(1)
Published: July 29, 2024
Abstract α-Synuclein (α-syn) accumulates as insoluble amyloid but also forms soluble α-syn oligomers (αSOs), thought to be even more cytotoxic than fibrils. To detect and block the unwanted activities of these αSOs, we have raised 30 monoclonal antibodies (mAbs) against different ranging from unmodified αSOs species stabilized by lipid peroxidation products polyphenols, formed C-terminally truncated α-syn, multivalent display on capsid virus-like particles (cVLPs). While mAbs generally show a preference for they bind fibrils, variable extents. Overall, observe great diversity in mAbs’ relative affinities monomers varied requirements C-terminal extension only modest effect fibrillation. Several several orders magnitude over in-solution studies, while commercial antibody MJF14 bound 10-fold strongly monomeric α-syn. Gratifyingly, seven almost completely αSO permeabilization membrane vesicles. Five selected identified α-syn-related pathologies like Lewy bodies (LBs) Neurites, well Glial Cytoplasmic Inclusions postmortem brains people diagnosed PD, dementia with LBs or multiple system atrophy, although Three were particularly useful pathological evaluation brain human tissue, including early stages PD. Although there was no straightforward connection between biophysical immunohistochemical properties, it is encouraging that this comprehensive collection able recognize aggregated vitro holds diagnostic potential.
Language: Английский
Citations
2
Biosensors, Journal Year: 2024, Volume and Issue: 14(11), P. 551 - 551
Published: Nov. 13, 2024
Plasmonic-based biosensors have gained prominence as potent optical biosensing platforms in both scientific and medical research, attributable to their enhanced sensitivity precision detecting biomolecular chemical interactions. However, the detection of low molecular weight analytes with high specificity remains a complex unresolved issue, posing significant limitations for advancement clinical diagnostic tools device technologies. Notably, abnormal cholesterol levels are well-established indicator various pathological conditions; yet, quantitative free form is complicated by its small size, pronounced hydrophobicity, necessity mediator molecules achieve efficient sensing. In present study, novel strategy quantification was developed, leveraging plasmonic readout conjunction highly specific cholesterol-binding peptide (C-pept) biorecognition element, anchored on functionalized silica substrate. The resulting biosensor exhibited an exceptionally limit 21.95 µM demonstrated linear response 10–200 range. This peptide-integrated sensor introduces one-step competitive method quantification, positioning itself sensitive modality implementation within AVAC platform, which operates using reflective dark-field microscopy.
Language: Английский
Citations
2
Talanta, Journal Year: 2024, Volume and Issue: 284, P. 127247 - 127247
Published: Nov. 19, 2024
Language: Английский
Citations
1